CLINICAL AND PHARMACOLOGIC DIFFERENCES OF CDK4/6 INHIBITORS IN BREAST CANCER

Targeted therapies such as Cyclin Dependent Safari Hat Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast cancer by combating the resistance seen with traditional endocrine therapy.The three approved agents currently in the market are palbociclib, ribociclib and abemaciclib.Besides th

Objectives: to determine the seroprevalence and the risk factors for cysticercosis in pig farm workers and traditional pig breeders living in the municipality of Mara in the state of Zulia.Methodology: Serum samples were studied from 59 individuals of both sexes (33 masculine and 26 feminine), with ages ranging from 1 to 60 years old, including 18